Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice
暂无分享,去创建一个
Giuseppe Battaglia | F. Nicoletti | F. Biagioni | F. Fornai | G. Battaglia | V. Bruno | Ferdinando Nicoletti | Francesca Biagioni | Francesco Fornai | C. Busceti | Valeria Bruno | Gemma Molinaro | M. Storto | G. Molinaro | Carla L Busceti | Marianna Storto
[1] Dementia in Parkinson's disease , 2001, Journal of Neurology.
[2] J. M. Mathiesen,et al. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB‐1893 and MPEP , 2003, British journal of pharmacology.
[3] P. Richardson,et al. Functional and molecular characterization of metabotropic glutamate receptors expressed in rat striatal cholinergic interneurones , 2002, Journal of neurochemistry.
[4] M. Mark. Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration. , 2001, Neurologic clinics.
[5] G. Corsini,et al. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. , 1997, The Journal of pharmacology and experimental therapeutics.
[6] G. Battaglia,et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.
[7] C. Holden. Excited by Glutamate , 2003, Science.
[8] S. Heinemann,et al. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems , 1999, Nature Neuroscience.
[9] S. Przedborski,et al. Mechanisms of MPTP toxicity. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[10] Y. Itoyama,et al. Neuroprotective effect of riluzole in MPTP-treated mice , 2001, Brain Research.
[11] A. Faden,et al. Selective mGluR5 antagonists MPEP and SIB‐1893 decrease NMDA or glutamate‐mediated neuronal toxicity through actions that reflect NMDA receptor antagonism , 2000, British journal of pharmacology.
[12] Y. Smith,et al. Differential Subcellular Localization of mGluR1a and mGluR5 in the Rat and Monkey Substantia Nigra , 2001, The Journal of Neuroscience.
[13] F. Nicoletti,et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 2003, Neuropharmacology.
[14] J. Roder,et al. Gene targeting reveals a role for the glutamate receptors mGluR5 and GluR2 in learning and memory , 2001, Physiology & Behavior.
[15] K. Ossowska. The role of excitatory amino acids in experimental models of Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[16] J. Costentin,et al. Correlation between (3H)dopamine specific uptake and (3H)GBR 12783 specific binding during the maturation of rat striatum. , 1989, Life sciences.
[17] Y. Smith,et al. Activation of Group I Metabotropic Glutamate Receptors Produces a Direct Excitation and Disinhibition of GABAergic Projection Neurons in the Substantia Nigra Pars Reticulata , 2001, The Journal of Neuroscience.
[18] A. Kanthasamy,et al. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease , 1997, Brain Research.
[19] Roland Heckendorn,et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.
[20] P. Calabresi,et al. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones , 1997, British journal of pharmacology.
[21] P. Worley,et al. Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.
[22] Z. Bortolotto,et al. A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG‐induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices , 2000 .
[23] C. Grillon,et al. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans , 2003, Psychopharmacology.
[24] G. Nappi,et al. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease , 2001, Annals of neurology.
[25] J. Roder,et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. , 1998, Learning & memory.
[26] J. Roder,et al. Mice Lacking Metabotropic Glutamate Receptor 5 Show Impaired Learning and Reduced CA1 Long-Term Potentiation (LTP) But Normal CA3 LTP , 1997, The Journal of Neuroscience.
[27] F. Nicoletti,et al. Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] J. Cano,et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.
[29] G. Robertson,et al. Pathophysiology of L-dopa-induced dyskinesias. , 1999, Movement Disorders.
[30] P Jeffrey Conn,et al. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. , 2002, Current drug targets. CNS and neurological disorders.
[31] K. Fuxe,et al. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury , 2001, Neuroreport.
[32] I. Kopin. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. , 1987, Environmental health perspectives.
[33] P. Calabresi,et al. Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons , 2001, Neuropharmacology.
[34] G. Collingridge,et al. Roles of metabotropic glutamate receptors in LTP and LTD in , 1999, Current Opinion in Neurobiology.
[35] P. Greengard,et al. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Beal,et al. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice , 1993, Neuroreport.
[37] D. S. Albers,et al. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.
[38] J. Cano,et al. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury , 2002, Neuroscience.
[39] B. Hyman,et al. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss , 1993, Neurobiology of Aging.
[40] M. Amalric,et al. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.
[41] P Jeffrey Conn,et al. Glutamate Receptors and Parkinson’s Disease , 2003, Drugs & aging.
[42] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[43] S. Ferré,et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[44] G. Page,et al. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes , 2001, Journal of neurochemistry.
[45] M. Kupersmith,et al. Dementia in Parkinson disease , 1979, Annals of neurology.
[46] R. Balázs,et al. Expression of metabotropic glutamate receptor 5 is increased in astrocytes after kainate‐induced epileptic seizures , 2000, Glia.
[47] R. Elble. Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.
[48] K. Fuxe,et al. The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors , 2001, Neuropsychopharmacology.
[49] A. Janowsky,et al. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. , 2003, Pharmacology & therapeutics.
[50] A. Faden,et al. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. , 2001, The Journal of pharmacology and experimental therapeutics.
[51] A. Charara,et al. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia , 2001, Journal of Chemical Neuroanatomy.
[52] K. Lange,et al. Glutamatergic drugs in Parkinson's disease. , 1994, Life sciences.
[53] J. Xuereb,et al. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5 , 2001, Experimental Brain Research.
[54] P. Conn,et al. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia , 2002, Amino Acids.
[55] D D Schoepp,et al. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. , 2000, British journal of pharmacology.
[56] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[57] F. Gasparini,et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.
[58] F. D. da Silva,et al. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy , 2000, The European journal of neuroscience.
[59] K. Lange,et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.
[60] G. Christoffersen,et al. Differential effects of mGluR1 and mGlur5 antagonism on spatial learning in rats , 2002, Pharmacology Biochemistry and Behavior.
[61] Y. Smith,et al. Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus , 2000, The Journal of Neuroscience.
[62] Joseph E LeDoux,et al. The Group I Metabotropic Glutamate Receptor mGluR5 Is Required for Fear Memory Formation and Long-Term Potentiation in the Lateral Amygdala , 2002, The Journal of Neuroscience.
[63] F. Nicoletti,et al. Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.
[64] D. Balschun,et al. Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats , 2002, Pharmacology Biochemistry and Behavior.
[65] D. Lovinger,et al. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. , 2001, Journal of neurophysiology.
[66] P. Conn,et al. Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata , 2002, Neuropharmacology.
[67] P. Calabresi,et al. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation , 2003, Neuropharmacology.
[68] F. Vaglini,et al. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice , 1994, Brain Research.
[69] P. Calabresi,et al. Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.
[70] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[71] E. Aronica,et al. Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes , 2001, Neuroscience.
[72] K. Lange,et al. MPTP-induced degeneration: interference with glutamatergic toxicity. , 1994, Journal of neural transmission. Supplementum.
[73] S. Parvez,et al. Cell death induced by MPTP, a substrate for monoamine oxidase B. , 2000, Toxicology.
[74] Y. Agid,et al. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures , 1992, Brain Research.
[75] G. Zeevalk,et al. MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats , 1992, Journal of neurochemistry.
[76] K. Fuxe,et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors , 2002, Neuroscience Letters.
[77] A. Kupsch,et al. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice , 1992, Brain Research.
[78] R. Ramsay,et al. Processing of MPTP by monoamine oxidases: implications for molecular toxicology. , 1987, Journal of neural transmission. Supplementum.